[The use of ceruloplasmin in combination with adjuvant polychemotherapy in stomach cancer].
Ceruloplasmin as a modulator was used for the first time in the clinical practice in 30 patients with gastric cancer in the course of postoperative intraabdominal adjuvant chemotherapy. It was established that ceruloplasmin was well tolerated by the patients and its use during polychemotherapy is accompanied by normalization of the levels of natural ceruloplasmin and iron in the blood serum that are usually reduced in patients with gastric cancer, reduces activation of lipid peroxidation and improves the course of postoperative period. Ceruloplasmin possesses a week immunomodulating action in polychemotherapy which is expressed in the increase of the percentage content of T-lymphocytes. Use of ceruloplasmin tended to improve the functional state of the cardiovascular system.
Shchepotin
I B
IB
Chernyĭ
V A
VA
Berdinskikh
N K
NK
Sanina
O L
OL
Baraboĭ
V A
VA
Starosel'skiĭ
I V
IV
Korobko
V B
VB
Kamenets
L Ia
LIa
Iaremenko
L Ia
LIa
D000276:Adjuvants, Immunologic; D000917:Antibody Formation / Q000187:drug effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002570:Ceruloplasmin / Q000009:adverse effects / Q000032:analysis / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006321:Heart / Q000187:drug effects; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007501:Iron / Q000097:blood; D015227:Lipid Peroxidation / Q000187:drug effects; D011182:Postoperative Care; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology
D000276:Adjuvants, Immunologic; D004317:Doxorubicin; D007501:Iron; D002570:Ceruloplasmin; D005472:Fluorouracil
Primenenie tseruloplazmina v sochetanii s ad''iuvantnoĭ polikhimioterapieĭ pri rake zheludke.